NCT06602258: An ongoing trial by Eisai Inc.
This trial is ongoing. It must report results 1 year, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06602258 |
|---|---|
| Title | A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 30, 2024 |
| Completion date | Dec. 3, 2026 |
| Required reporting date | Dec. 3, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |